NCT01871779

Brief Summary

Cardiovascular disease remain one of the leading causes of death in Australia, accounting for 47637 (36%) of deaths in 2004. Peripheral arterial disease (PAD) is a category of cardiovascular disease, characterised by intermittent claudication. This is defined as walking induced pain, cramping, aching, tiredness or heaviness in one or both legs that does not go away with continued walking and is relieved with rest. It is estimated that between 5-10% of individuals aged over 50 years suffer from claudication. The primary and most effective treatment for these patients is focused on improving walking ability and functional status. Current research has shown that approximately 30% of patients improve with exercise, while 30% continue to deteriorate and the rest show no change. The changes produced at a biochemical and cellular level due to exercise are unknown. To help better understand this, our study will assess the entire range of proteins expressed before and after exercise in the skeletal muscle tissue of patients with intermittent claudication. This will help to identifying key proteins that have a role in improving patient symptoms and outcome.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2010

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2010

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2013

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 31, 2013

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 7, 2013

Completed
Last Updated

June 7, 2013

Status Verified

June 1, 2013

Enrollment Period

2.2 years

First QC Date

May 31, 2013

Last Update Submit

June 4, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • Improvement in Pain Free Walking Distance

    Patients will be exercised based on standard protocols and monitored for improvements in Maximal walking distance and Pain Free Walking distances.

    Change from baseline (pre intervention) to 12 weeks (post intervention)

Secondary Outcomes (3)

  • Skeletal muscle protein expression

    Change from baseline (pre intervention) to 12 weeks (post intervention)

  • Inflammatory cytokines

    Change from baseline (pre intervention) to 12 weeks (post intervention)

  • Endothelial function

    Change from baseline (pre intervention) to 12 weeks (post intervention)

Study Arms (2)

Standard Treadmill Exercise

EXPERIMENTAL

The first group would undergo standard treadmill exercise to the point of pain and repeat these cycles for a total period of 35-45 minutes twice weekly for 12 weeks

Other: Standard Treadmill Exercise

Intermittent Treadmill & Resistance Training

EXPERIMENTAL

The second group would have a combination of intermittent treadmill and some resistance training with weights. They will undergo repeated cycles to a maximum of 35-45 minutes twice weekly for 12 weeks

Other: Intermittent treadmill & resistance training

Interventions

Standard treadmill exercise to the point of pain twice weekly for 35-45 minutes for 12 weeks

Standard Treadmill Exercise

Combination of standard treadmill training and resistance training with weights twice weekly for 12 weeks

Intermittent Treadmill & Resistance Training

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • All claudicants with a walking distance of 50 metres or more with a resting ankle brachial index equal to or less than 0.9.
  • Claudicants meeting above criteria, who may have previously had a percutaneous arterial intervention for symptom control more than 12 months ago.

You may not qualify if:

  • Patients with lower limb pain of other aetiologies - neurogenic claudication evidenced by normal ankle brachial indices and duplex ultrasound.
  • Patients with lower limb ischaemic rest pain
  • Patients with current or previous tissue loss, such as ulcers or necrotic lesions.
  • Patients with recent (\<12 months) history of peripheral vascular interventions for symptoms.
  • Patients with pre-existing cardiac or respiratory problems limiting exercise.
  • Patients with previous disabling strokes which would restrict exercise regimes
  • Patients with anticoagulation or blood dyscrasias.
  • Women who are pre-menopausal,
  • Women receiving hormone-replacement therapy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Repatriation General Hospital

Daw Park, South Australia, 5041, Australia

Location

Related Publications (1)

  • Delaney CL, Miller MD, Dickinson KM, Spark JI. Change in dietary intake of adults with intermittent claudication undergoing a supervised exercise program and compared to matched controls. Nutr J. 2014 Oct 15;13:100. doi: 10.1186/1475-2891-13-100.

MeSH Terms

Conditions

Peripheral Arterial Disease

Interventions

Resistance Training

Condition Hierarchy (Ancestors)

AtherosclerosisArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesPeripheral Vascular Diseases

Intervention Hierarchy (Ancestors)

Exercise TherapyRehabilitationAftercareContinuity of Patient CarePatient CareTherapeuticsPhysical Therapy ModalitiesPhysical Conditioning, HumanExerciseMotor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Christopher L Delaney, BMBS

    Flinders University and Flinders Medical Centre Department of Vascular Surgery

    PRINCIPAL INVESTIGATOR
  • James I Spark, MBChB, MD,

    Flinders University and Flinders Medical Centre Department of Vascular Surgery

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

May 31, 2013

First Posted

June 7, 2013

Study Start

October 1, 2010

Primary Completion

December 1, 2012

Study Completion

February 1, 2013

Last Updated

June 7, 2013

Record last verified: 2013-06

Locations